Industry & Satellite Symposia are programs held at the IASLC 2021 Targeted Therapies on Lung Cancer (TTLC 2021), are not sponsored or endorsed by the IASLC are not part of the official IASLC accredited program.
Day 1: February 17
Day 2: February 18
18:10 – 19:10 EST Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC) by Jazz Pharmaceuticals, Inc.
Chair: Christine Culligan
Speakers: Leo Shunyakov, MD
Join us for this expert-led program where we will explore:
An overview of unmet needs in SCLC
Current treatment guidelines for SCLC
Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC
Considerations for dosing, administration, and patient counseling
18:10 – 19:10 EST New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer by Peerview
Roy S. Herbst, MD, PhD
Lecia V. Sequist, MD, MPH
Advances in the management of patients with EGFR-mutated non–small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team.
This PeerView Live web broadcast will provide expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. The importance of patient education and engagement in decisions and how to overcome current health disparities in lung cancer will be addressed as well. Join the discussion, and learn what you can do to help improve outcomes for patients with early lung cancer.
Keep up to date with the latest news & alerts. Sign Up